Expert Interview
Discussing the potential use of PD-L1 agonists in treating Rheumatoid Arthritis
Ticker(s): LLY, ANABInstitution: Medical College of Wisconsin
- Assistant Professor of Medicine, Medical Director of the Vasculitis program.
- Research interests include clinical trials in vasculitis and myositis, "big data" epidemiology, and meta-research.
- Associate editor of the journal Rheumatology and hosts the Evidence Based Rheumatology podcast.
Can you provide an overview of your background, research interests, and your clinical practice, particularly related to vasculitis and myositis?
What are your general thoughts on the use of PD-1 agonists in treating autoimmune diseases, particularly rheumatoid arthritis?
What is your perspective on the best approach for targeting PD-1, including proximal versus distal binding, in autoimmune diseases?
How do you compare the efficacy and safety of depletion versus agonism in immune system modulation for autoimmune diseases?
Do you have concerns about the potential for PD-1 agonists to induce receptor endocytosis and subsequent antagonism over time?
What are your thoughts on the potential infection risks associated with PD-1 agonists, based on your experience with other immunomodulatory therapies?
How do you assess the potential risks of cancer development with long-term use of PD-1 agonists, and what factors might mitigate these risks?
Added By: slingshot_insightsBeyond rheumatoid arthritis, which other autoimmune diseases or conditions do you think could benefit from PD-1 agonists, and why?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
